cornerstone - Bioenergetic Technology

Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome

Uncategorized cornerstone, fda, growing, has-granted, the-growing, today-announced

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the U.S.

Visit link:
Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome

Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 for the Treatment of Myelodysplastic Syndrome

Uncategorized announced-the-initiation, clinical-, cornerstone, growing, initiation, phase, the-growing, the-initiation, today-announced

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase II clinical …

View original post here:
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 for the Treatment of Myelodysplastic Syndrome